Marja T. Nevalainen, MD, PhD

Professor, Eminent Scholar Department of Pathology and Pharmacology & Toxicology Assistant Dean of Research, Medical College of Wisconsin Associate Director (Education), Medical College of Wisconsin Cancer Center Director, Prostate Cancer Center of Excellence, Medical College of Wisconsin Cancer Center

Contact Information

Biography

Marja Nevalainen, MD, PhD is an internationally recognized leader in the field of cytokine and steroid hormone signaling in prostate cancer. The focus of her laboratory is on translational prostate cancer research to develop and improve diagnostics and therapy for prostate cancer. Dr. Nevalainen holds the title of Eminent Scholar at MCW. She is also Director of Prostate Cancer Center of Excellence at MCW Cancer Center, which is a multi-disciplinary hub for prostate cancer research within the institution with an international collaborative network. Dr. Nevalainen serves as Assistant Dean for Research at MCW, and Associate Director of Education for the MCW Cancer Center. Her primary appointment is in the Department of Pathology, and a secondary appointment in the Department of Pharmacology and Toxicology. Dr. Nevalainen has extensive experience in collaborative research, mentoring and leadership from her previous roles at Sidney Kimmel Cancer Center at Thomas Jefferson University as Associate Director of Education and Vice Chair of Education in the Department of Cancer Biology.

Honors and Awards

General Medicine Board Certification

Education

University of Turku, School of Medicine, Turku, Finland, MD
University of Turku, Turku, Finland, Cell Biology, PhD

Research Interests

Jak-Stat signaling
Prostate cancer progression
Therapy development
Companion diagnostics
Predictive Factors
DNA repair
Radiation therapy
In vitro and in vivo models
3D tumor explant culture
Epithelial-mesenchymal transition
Cancer stem-like cell properties
Metastases models
Small molecule therapeutics

Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

(Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B.) Cancer Res. 2018 Oct 15;78(20):5793-5807.
Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer.

(McGarry SD, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS.) Int J Radiat Oncol Biol Phys. 2018 Aug 01;101(5):1179-1187.
STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.

(Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT.) Clin Cancer Res. 2018 Apr 15;24(8):1917-1931.
Optimized -value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging.

(Hurrell SL, McGarry SD, Kaczmarowski A, Iczkowski KA, Jacobsohn K, Hohenwalter MD, Hall WA, See WA, Banerjee A, Charles DK, Nevalainen MT, Mackinnon AC, LaViolette PS.) J Med Imaging (Bellingham). 2018 01;5(1):011004.
Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

(Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.) Sci Rep. 2017 Sep 06;7(1):10693.
ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

(Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.) Sci Rep. 2017 04 24;7(1):1109.
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

(Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.) Mol Cancer. 2016 11 10;15(1):70.
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

(Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.) Oncotarget. 2017 Jan 10;8(2):3724-3745.
Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype.

(Singh A, Fedele C, Lu H, Nevalainen MT, Keen JH, Languino LR.) Mol Cancer Res. 2016 11;14(11):1136-1146.
Peptidylarginine Deiminase 3 (PAD3) Is Upregulated by Prolactin Stimulation of CID-9 Cells and Expressed in the Lactating Mouse Mammary Gland.

(Li G, Hayward IN, Jenkins BR, Rothfuss HM, Young CH, Nevalainen MT, Muth A, Thompson PR, Navratil AM, Cherrington BD.) PLoS One. 2016;11(1):e0147503.
Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

(Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.) Am J Pathol. 2015 Sep;185(9):2505-22.
Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

(Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT.) Mol Cancer Ther. 2015 Aug;14(8):1777-93.

Marja T. Nevalainen, MD, PhD